Triple-Drug cocktail boosts survival in unresectable liver cancer
NCT ID NCT07321613
First seen Jan 10, 2026 · Last updated May 16, 2026 · Updated 23 times
Summary
This study tested whether adding a three-drug cocktail (thalidomide, carmofur, and compound mylabris capsules) to the standard procedure called TACE could help people with liver cancer that cannot be removed by surgery. Researchers looked at 545 patients and measured how long they lived and how well their tumors responded. The goal was to see if the combination treatment improved outcomes compared to TACE alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CANCER (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zhongshan Hospital, Fudan University
Shanghai, China
Conditions
Explore the condition pages connected to this study.